• Fri. Jan 21st, 2022

Sbraccia (Tor Vergata): “New weight loss therapy against obesity”

Byeditorial

Jun 4, 2021

“Obesity has for too long been thought of as a simple nutritional disorder. In fact it is a very serious disease, as well as an important risk factor for major chronic diseases including diabetes, hypertension, cancer and a whole range of osteoarthritis. therefore treated as early as possible. Up to now we have not had many tools, however new drugs of extreme interest are appearing, such as the therapy with semaglutide that makes you lose weight and improves the quality of life of patients, as confirmed by the Step 1 study presented at the recently concluded European Congress on Obesity 2021 (Eco2021) “. This was stated to Adnkronos Salute Paolo Sbraccia, director of Internal Medicine and Obesity Medical Center of the Tor Vergata Polyclinic in Rome. Overweight and obesity concern 25 million Italians, 46.1% of the adult population, according to the annual analysis carried out by Istat for the Italian Obesity Barometer Report. The report shows how women show a lower obesity rate (9.4%) than men (11.8%) and how the phenomenon of excess weight is a widespread problem especially in the South and in the Islands. “During Eco2021 – explains Sbraccia – the results of the so-called Step 1 program were presented and discussed. These are the data of the use of a new drug, of an innovative dosage of a therapy recently used in diabetic patients, semuglutide a 2 , 4 mg once a week, which reduces appetite and increases satiety. The results showed weight loss rates close to 20%. This is data that approaches gastric band, a surgical procedure, so it leaves well hope for highly effective use in patients with obesity. “In addition to allowing significant weight loss, according to the data brought to Eco2021, active treatment was associated with greater improvements than placebo in all quality scores of life related to weight and health. “Those who took semaglutide improved well-being, understood as having more energy, and increased self-confidence,” confirms Sbraccia. 43.8% – the study reads – achieved a clinically significant improvement in the weight-related quality of life score. In addition, more than half (51.2%) of the semaglutide group increased their weight-related physical function score, which indicates improvements in the ability to perform daily physical activities such as tying shoes and walking. “Semaglutide is a latest generation Glp-1 receptor agonist drug – concludes Sbraccia – It helps to lose weight by reducing hunger and increasing the feeling of satiety: in this way people eat less”. The drug, not yet available in Italy, is currently undergoing regulatory review in several countries, including the United States FDA and the European Medicines Agency (EMA).

One thought on “Sbraccia (Tor Vergata): “New weight loss therapy against obesity””
  1. editorial says:

    https://connect.informs.org/network/members/profile?UserKey=9d9473b2-2ef0-461c-85d9-59c770749c94
    https://connect.informs.org/network/members/profile?UserKey=43ef444f-2d92-47ed-9831-e7b6b2fb3601
    https://connect.informs.org/network/members/profile?UserKey=e8f3726f-562d-46c6-8c7f-7616a62c3d18
    https://connect.informs.org/network/members/profile?UserKey=89f55fa7-5427-4c12-af00-b378bb45b0b4
    https://connect.informs.org/network/members/profile?UserKey=64eb11e6-d2ae-42cb-9270-3c2be1484098
    https://connect.informs.org/network/members/profile?UserKey=53d6af24-85d7-4c02-9db7-4df094bb4f04
    https://connect.informs.org/network/members/profile?UserKey=828801da-c89b-4bcd-bf76-cffd6d2f8ada
    https://connect.informs.org/network/members/profile?UserKey=d5bf32ae-c2a1-455b-b7e8-edfa7b93a358
    https://connect.informs.org/network/members/profile?UserKey=34ae1415-c193-4b7e-98ea-3c5c9ae131dd
    https://connect.informs.org/network/members/profile?UserKey=446b38b9-1df4-4dab-bf92-fc837691d692
    https://connect.informs.org/network/members/profile?UserKey=58845cfe-e8c4-4fb9-be2c-2ee455ba590d
    https://connect.informs.org/network/members/profile?UserKey=376000f9-48fc-4539-aceb-09dcc1436d6f
    https://connect.informs.org/network/members/profile?UserKey=a8be5288-056a-4497-a673-02075ffc7928
    https://connect.informs.org/network/members/profile?UserKey=4ec4bde1-f002-4f71-865f-8a9b94198cb8
    https://connect.informs.org/network/members/profile?UserKey=6bebc504-9c3e-4dbe-bcc4-4c8db93fd53b
    https://connect.informs.org/network/members/profile?UserKey=3dfa27ca-22d2-457f-a7ba-f2498bc553ad
    https://connect.informs.org/network/members/profile?UserKey=b3c04b28-d81f-4b64-af69-51a70f3e245a
    https://connect.informs.org/network/members/profile?UserKey=bd59ad40-d3d3-4616-bb4c-05f87fb9947c
    https://connect.informs.org/network/members/profile?UserKey=976509d8-21b5-42d2-af75-a4fd02cacbb9
    https://connect.informs.org/network/members/profile?UserKey=ecd3a3d5-7eb5-4057-90c2-9d2e1a05044b
    https://connect.informs.org/network/members/profile?UserKey=6a93aad4-0cd4-4641-8bf3-ff4a8fd7b6c1
    https://connect.informs.org/network/members/profile?UserKey=923ee474-2e35-43d7-8585-579f264a3042
    https://connect.informs.org/network/members/profile?UserKey=c75f00de-6a2d-4bfb-bf76-7fcf4c364320
    https://created.crayola.com/network/members/profile?UserKey=9429bc85-b222-42c4-b405-1b36e2306441
    https://created.crayola.com/network/members/profile?UserKey=32a7d35b-6634-4935-aa3b-f0e436675f1d
    https://created.crayola.com/network/members/profile?UserKey=dfa94344-b03a-4376-80a8-e1314b3191c7
    https://created.crayola.com/network/members/profile?UserKey=063f7d8c-f2e3-4bf7-a41f-4e5398c83740
    https://created.crayola.com/network/members/profile?UserKey=fddffadd-bdb6-48e4-bb2e-fbbc5abbae9d
    https://created.crayola.com/network/members/profile?UserKey=c624eb0b-5391-4190-a3cd-6697365ba322
    https://created.crayola.com/network/members/profile?UserKey=599f731e-ac7b-425c-a0ca-237808869627
    https://created.crayola.com/network/members/profile?UserKey=f594c6a8-cc07-454e-801a-e603d6966fe1
    https://created.crayola.com/network/members/profile?UserKey=2b110639-07c3-45e7-9013-b60817d18a11
    https://created.crayola.com/network/members/profile?UserKey=9bd3dd5a-6f14-4a86-9f4e-e3032ff0e07c
    https://created.crayola.com/network/members/profile?UserKey=36c64d73-213f-4fd2-a5de-e3f4a2333ff6
    https://created.crayola.com/network/members/profile?UserKey=adcc9e98-ff85-4440-80ec-b7b4d6e73bb2
    https://created.crayola.com/network/members/profile?UserKey=3fcf4895-0110-46d3-84fe-965a86da0827
    https://spiible.com/institutions/downloadmp3-natural-healing-%E3%81%90%E3%81%A3%E3%81%99%E3%82%8A%E7%9C%A0%E3%82%8C%E3%82%8B%E3%83%AA%E3%83%A9%E3%82%AF%E3%82%B7%E3%83%B3%E3%82%B0bgm-%E8%87%AA%E7%84%B6%E3%81%AE%E9%9F%B3%E3%81%A7%E5%BF%83%E3%82%92%E7%99%92%E3%81%99-album-download
    https://created.crayola.com/network/members/profile?UserKey=9db84216-0422-445d-b720-0acfdacbba8c
    https://created.crayola.com/network/members/profile?UserKey=5ce58354-7eb6-4d0c-afe1-34649958b1e6
    https://telegra.ph/Download-Joana—Playlist—As-Melhores-2021-Album-06-04
    https://telegra.ph/Download-MIRIANNY-VALLADARES—Sabana-Rancho-y-Recuerdo-2021-Album-06-03
    https://created.crayola.com/network/members/profile?UserKey=83ca5d9d-944a-4d88-8a42-d1f6b435f127
    https://spiible.com/institutions/downloadmp3-rachelle-allison-si-j%C3%A9tais-pire-album-download
    https://created.crayola.com/network/members/profile?UserKey=801c6a8f-3012-4459-bcea-74d60e624f81
    https://created.crayola.com/network/members/profile?UserKey=ef7f8acf-dca9-4424-ba66-601d29a19d10
    https://created.crayola.com/network/members/profile?UserKey=13019f81-3ebe-4897-b78e-c359c79119b6
    https://spiible.com/institutions/download-album-new-reign-arjun-night-zip-mp3
    https://created.crayola.com/network/members/profile?UserKey=ad8c0ee0-29c7-4d46-8b0f-9a6fd559fb8b
    https://created.crayola.com/network/members/profile?UserKey=f95389fa-5ef7-42f6-89cf-49f58e2e74fa
    https://created.crayola.com/network/members/profile?UserKey=ccb027cd-a41b-4101-9760-967f12b38202

Comments are closed.